wild/抗真菌药

TECHNICAL AREA OF THE INVENTION The invention relates to the area of cancer diagnostics. More particularly, the invention relates to detection of the loss and or alteration of wild-type huBUB1 genes in tumor tissues. BACKGROUND OF THE INVENTION Genes and proteins involved in cell cycle regulation

This application is the U.S. National Phase under 35 U.S.C. .sctn.371 of International Application PCT Patent Application No. PCT/KR2004/001941, filed on Aug. 2, 2004, which claims priority to Korean Patent Application No. 10-2004-055088, filed on Jul. 15, 2004, the contents of which are all herein

The present invention relates to biomarkers for determining the sensitivity of proliferative diseases such as cancer to therapeutic agents, in particular mTOR inhibitors in combination with a cytotoxic agent. A number of mTOR inhibitors have potent antiproliferative properties which make them useful

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a U.S. national phase of International Application No. PCT/KR2009/006523 filed on Nov. 6, 2009, which claims the benefit of Korean Application No. 10-2008-0110086 filed on Nov. 6, 2008, the contents of which are hereby incorporated by

FIELD OF THE INVENTION The present invention relates to a composition for preventing or treating acquired immunodeficiency syndrome (AIDS), comprising one or more of the following: a cell line derived from the cambium of Panax ginseng including wild ginseng and ginseng, and a lysate, an extract and

The present invention provides RANTES mutants with reduced pro-inflammatory activity, increased HIV-suppressive activity, and antagonistic activity to wild-type chemokines. Chemokines are small proteins involved in inflammatory mechanisms and in physiologic circulation of hemopoietic cells. Several

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 11, 2015, is named 37151-706.601_SL.txt and is 113,105 bytes in size. BACKGROUND OF

The present invention provides RANTES mutants with reduced pro-inflammatory activity, increased HIV-suppressive activity, and antagonistic activity to wild-type chemokines. Chemokines are small proteins involved in inflammatory mechanisms and in physiologic circulation of hemopoietic cells. Several

FIELD OF THE INVENTION This invention pertains to therapeutics for the treatment of synovial sarcoma. BACKGROUND OF THE INVENTION Human synovial sarcoma (SS) is a soft tissue sarcoma that is associated with a translocation event, t(X;18)(p11.2;q11.2), which fuses the SS18 gene on chromosome 18 to

FIELD OF THE INVENTION This invention pertains to therapeutics for the treatment of synovial sarcoma. BACKGROUND OF THE INVENTION Human synovial sarcoma (SS) is a soft tissue sarcoma that is associated with a translocation event, t(X; 18)(p11.2; q11.2), which fuses the SS18 gene on chromosome 18 to

BACKGROUND OF THE INVENTION I. Field of the Invention This invention is directed to tissue plasminogen activator (t-PA) variants having extended circulatory half-life as compared to wild-type human t-PA while substantially retaining its fibrin binding affinity. Certain variants additionally exhibit

TECHNICAL FIELD The present invention relates to various functional variants of recombinant protein S (PS) that do not significantly bind C4b binding protein (C4BP) and uses of the variants as a therapeutic reagent. BACKGROUND Protein S (PS) is a vitamin K-dependent protein of 75,000 molecular

TECHNICAL FIELD The present invention relates to various functional variants of recombinant protein S (PS) that do not significantly bind C4b binding protein (C4BP) and uses of the variants as a therapeutic reagent. BACKGROUND Protein S (PS) is a vitamin K-dependent protein of 75,000 molecular

FIELD The present invention generally relates to systems and method for delivery of therapeutic gas to patients in need thereof using enhanced breathing circuit gas (BCG) flow measurement. BACKGROUND Therapeutic gas can be delivered to patients, in need thereof, to provide medical benefits. One such

FIELD The present invention generally relates to systems and method for delivery of therapeutic gas to patients in need thereof using enhanced breathing circuit gas (BCG) flow measurement. BACKGROUND Therapeutic gas can be delivered to patients, in need thereof, to provide medical benefits. One such